Atyr PHARMA’s (ATYR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $35.00 price objective on the stock.

Several other analysts have also recently weighed in on the stock. Jefferies Financial Group began coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $16.00 target price on shares of Atyr PHARMA in a research note on Wednesday, August 14th. Finally, Wells Fargo & Company started coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target on the stock.

Atyr PHARMA Stock Performance

NASDAQ:ATYR opened at $3.27 on Tuesday. The firm has a 50 day moving average of $2.88. The firm has a market capitalization of $274.49 million, a PE ratio of -3.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a one year low of $1.14 and a one year high of $3.80.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.01). As a group, analysts predict that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.